Sandoz Group (SDZNY) Stock Price, News & Analysis

Company Overview

Sandoz Group AG is a Switzerland-based pharmaceutical company focused on developing, manufacturing and supplying generic and biosimilar medicines. Its portfolio includes products across areas such as anti-infectives, immunology, oncology, ophthalmology, respiratory care and cardiovascular medicine, as well as injectable and specialty pharmaceuticals.

The company traces its origins to Sandoz, founded in Basel in 1886, and became an independent business through its separation from Novartis in 2023. Sandoz shares began trading independently on the SIX Swiss Exchange in October 2023, while the company’s American depositary shares trade over the counter in the United States under the symbol SDZNY.

Headquartered in Basel, Switzerland, Sandoz serves patients and healthcare providers in more than 150 countries through a global network of manufacturing, research and commercial operations. The company’s business emphasizes expanding access to lower-cost medicines and advancing biosimilars, which are biologic medicines designed to be highly similar to approved reference products.

Key Stats

• Today's Range: $81.68 to $83.29
• 50-Day Range: $77.92 to $93.01
• 52-Week Range: $55.42 to $94.15
• Volume: 17,422 shs
• Average Volume: 18,042 shs
• Market Capitalization: $36.00 billion
• P/E Ratio: N/A
• Dividend Yield: 0.75%
• Price Target: N/A
• Consensus Rating: Strong Buy

Sandoz Group Stock Analysis - MarketRank™

Sandoz Group scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Sandoz Group has received a consensus rating of Strong Buy. The company's average rating score is 3.60, and is based on 4 strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Sandoz Group has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 13.11%

Earnings Growth

Earnings for Sandoz Group are expected to grow by 13.11% in the coming year, from $4.12 to $4.66 per share.

Price to Earnings Growth Ratio

Sandoz Group has a PEG Ratio of 1.63. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Sandoz Group has a P/B Ratio of 3.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.03% of the float of Sandoz Group has been sold short.

Short Interest Ratio / Days to Cover

Sandoz Group has a short interest ratio ("days to cover") of 4.12.

Change versus previous month

Short interest in Sandoz Group has recently increased by 2.46%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Sandoz Group has a dividend yield of 0.74%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Sandoz Group does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Sandoz Group will have a dividend payout ratio of 13.09% next year. This indicates that Sandoz Group will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.60

News Sentiment

Sandoz Group has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Sandoz Group this week, compared to 0 articles on an average week.

Search Interest

2 people have searched for SDZNY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sandoz Group insiders have not sold or bought any company stock.

Percentage Held by Institutions

0.05% of the stock of Sandoz Group is held by institutions.

Company Calendar

• Today: 9/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:SDZNY
• CIK: 1992829
• Web: www.sandoz.com
• Phone: 41-61-324-11-11
• Fax: N/A
• Employees: 23,567
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 19.86
• P/E Growth: 1.63
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.53
• Current Ratio: 1.18
• Quick Ratio: 0.77

Sales & Book Value

• Annual Sales: $11.09 billion
• Price / Sales: 3.25
• Cash Flow: $3.64 per share
• Price / Cash Flow: 22.45
• Book Value: $21.33 per share
• Price / Book: 3.84

Miscellaneous

• Outstanding Shares: 440,000,000
• Free Float: N/A
• Market Cap: $36.00 billion
• Optionable: Not Optionable
• Beta: 0.57